Iceland· IS-EU/1/15/1031/004-006

Praluent

A alirocumab product containing alirocumabum inn, registered in Iceland by Sanofi Winthrop Industrie. The same ATC class is registered in 15 of our 19 countries.

ATC C10AX14

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedPraluentATCC10AX14REGISTER NO.IS-EU/1/15/1031/004-0…PACKS LISTED0CHECKEDSeptember 29, 2026

Where it is registered

Alirocumab is registered in 15 of 19 countries.

Countries holding a registration under ATC C10AX14 (alirocumab), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 10 of them publish a price we can compare per daily dose

Alirocumab · ATC C10AX14

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of alirocumab costs, country by country.

Normalised to the WHO defined daily dose (5.4 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Alirocumab · price per daily dose (5.4 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$16.93
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Alirocumabum INN
Manufacturer
Sanofi Winthrop Industrie
Country
Iceland (IS)
ATC code
C10AX14
ATC class
Alirocumab
Defined daily dose
5.4 mg, P
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/c7c46d9c-3496-4814-8ab0-3a628bb2b444
GET /v1/drugs/c7c46d9c-3496-4814-8ab0-3a628bb2b444?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stungulyf, lausn í áfylltri sprautu",
  "source": "lyfjastofnun",
  "atc_raw": "C10AX14",
  "marketed": false,
  "strength": "75 mg",
  "ma_number": "EU/1/15/1031/004-006",
  "substance": "Alirocumabum INN",
  "other_info": null,
  "legal_status": "(R) Lyfseðilsskylt",
  "ma_issued_serial": "42270"
}

See everything about alirocumab.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.